Cell type-associated traits map for the [MacParland_2018_liver_Erythroid cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [MacParland_2018_liver_Erythroid cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 5.00e-2 | 4.87e-2 |
Age At Menopause | Age At Menopause | ETC | Day | 2015 | NA | 2545 | 1.00e-2 | 3.47e-2 |
Age At Menopause | Age At Menopause | ETC | Day | 2015 | NA | 2545 | 1.00e-3 | 5.23e-3 |
Age At Menopause | Age At Menopause | ETC | Day | 2015 | NA | 2545 | 1.00e-4 | 2.59e-2 |
Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-2 | 9.78e-3 |
Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-3 | 2.16e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-3 | 4.38e-2 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 4.80e-2 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-3 | 8.34e-3 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 1.55e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-3 | 4.40e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 1.47e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 7.22e-5 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.43e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 2.44e-3 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 1.06e-4 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-5 | 6.32e-5 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-2 | 2.02e-2 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-3 | 3.86e-3 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-3 | 8.29e-3 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-5 | 1.06e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 5.00e-2 | 4.46e-2 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 2.53e-8 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 4.87e-12 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 1.42e-13 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 9.53e-16 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 5.00e-2 | 1.63e-2 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 3.43e-2 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 5.00e-2 | 4.91e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-2 | 7.94e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-3 | 4.15e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 5.00e-2 | 3.83e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 5.00e-2 | 1.72e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-2 | 2.87e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-3 | 2.55e-4 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-4 | 4.35e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 1.42e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 6.06e-3 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 2.99e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 9.89e-3 |
Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 4.54e-2 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 2.01e-2 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 5.01e-3 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-2 | 1.18e-3 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.89e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.77e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 3.75e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-5 | 1.16e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.84e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 6.39e-3 |
BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.21e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.49e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.24e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 3.99e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 4.28e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 6.62e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 3.34e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 1.83e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-3 | 2.03e-2 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 4.84e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 3.52e-2 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-2 | 9.51e-5 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-3 | 1.00e-3 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-4 | 2.60e-3 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 8.60e-3 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 1.50e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-2 | 4.64e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 3684 | 5.00e-2 | 4.81e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-3 | 3.44e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 3.31e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-3 | 1.74e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 7.28e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 5.00e-2 | 4.33e-2 |
Educational Attainment | Education Years Men | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 3.55e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 3.55e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.99e-2 |
Facial Shape | Mod30 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.30e-2 |
Facial Shape | Mod42 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.01e-2 |
Facial Shape | Mod42 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.97e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.81e-2 |
Facial Shape | Mod57 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.08e-2 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 8.93e-3 |
Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-2 | 4.44e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 16434 | 5.00e-2 | 3.08e-3 |
Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 2.61e-2 |
Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 1.08e-3 |
Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 1.09e-3 |
Glycemic Traits | Fasting Glucose | ETC | Dupuis | 2010 | NA | 46186 | 5.00e-2 | 8.73e-3 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 4.26e-2 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-3 | 1.97e-2 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-4 | 2.02e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 2.64e-4 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 9.47e-4 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 8.81e-4 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 3.94e-5 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 1.55e-5 |
Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 4.63e-2 |
Kidney Function | Rapid Decline Without Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 3.25e-3 |
Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 1.69e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 1.58e-2 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 6.89e-3 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.32e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.11e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.71e-2 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.59e-4 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 6.31e-3 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 4.52e-2 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 4.91e-2 |
Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.18e-2 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 1.09e-2 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 1.25e-2 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 2.45e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 2.17e-3 |
Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 5.00e-2 | 1.81e-2 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 5.00e-2 | 3.76e-3 |
Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 2.17e-2 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 2.40e-3 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 1.73e-3 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-2 | 2.10e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-4 | 1.50e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 6.37e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 5.52e-3 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 5.00e-2 | 9.30e-4 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 1.89e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 3.14e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 2.70e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 1.43e-2 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 2.46e-8 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 7.85e-9 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.76e-10 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 1.39e-9 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 1.99e-10 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 4.98e-2 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 4.72e-3 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 3.12e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.98e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 2.95e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-3 | 3.88e-2 |
Sleep | Sleep duration, short sleep | ETC | Dashti | 2019 | 106192 | 305742 | 1.00e-4 | 4.99e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 5.00e-2 | 3.10e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-2 | 2.74e-2 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-2 | 3.04e-3 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 1.00e-3 | 1.00e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 1.14e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 2.82e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 2.94e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 5.00e-2 | 1.30e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-2 | 3.35e-2 |
Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 1.00e-3 | 1.80e-2 |
Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 1.00e-4 | 5.36e-3 |
Life satisfaction | Life satisfaction | ETC | Baselmans | 2019 | NA | 80852 | 5.00e-2 | 3.24e-2 |
Life satisfaction | Life satisfaction | ETC | Baselmans | 2019 | NA | 80852 | 1.00e-2 | 5.50e-3 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.72e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.78e-2 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.64e-2 |
Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.40e-2 |
Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.69e-2 |
Parasubiculum volume | Parasubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.76e-3 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.89e-2 |
Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 1.08e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 9.00e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 7.04e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 9.05e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 1.06e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 1.05e-2 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-2 | 4.54e-2 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-3 | 1.15e-2 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 3.14e-3 |
Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 8.23e-4 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-3 | 4.32e-2 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-3 | 2.88e-2 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-4 | 4.76e-2 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.39e-2 |
Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 4.88e-3 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 1.66e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 3.48e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 8.90e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT5) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 4.32e-2 |
Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.29e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 1.84e-2 |
Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 1.24e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 1.87e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 4.00e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-3 | 3.81e-2 |
Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.09e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-3 | 1.41e-2 |
Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 1.00e-3 | 6.20e-3 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 1.67e-2 |
Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-2 | 9.30e-3 |
Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-3 | 4.72e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 9.39e-3 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 3.21e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 2.52e-3 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.67e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 4.61e-2 |
Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 5.00e-2 | 1.08e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 3.02e-2 |
BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 5.51e-3 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 1.60e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 2.12e-2 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 3.33e-3 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 4.76e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 7.74e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.86e-4 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 3.78e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 2.95e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-4 | 4.15e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-5 | 4.93e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 2.34e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 2.99e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 1.99e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-2 | 3.10e-2 |
Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 1.84e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.80e-2 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 5.50e-4 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 3.47e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.